Familial defective apolipoprotein (apo) B-IOO (FDB) is an autosomal codominant disorder, which may be associated with hypercholesterolaemia. The defect is caused by the substitution of glutamine for arginine at amino acid residue 3500 of apo B-100. A total of 357 hypercholesterolaemic patients, 48 with a clinical diagnosis of familial hypercholesterolaemia attending lipid clinics in Scotland and Wales, were screened for the presence of FDB. Seven unrelated individuals, five of whom had a family history of coronary heart disease, and a further II first-degree relatives, were shown to be heterozygous for the mutation. Pedigree analysis demonstrated the mutation to be present on a single haplotype, suggesting that in Britain it is inherited from a common ancestor. Treatment of II heterozygous individuals with lipid-lowering medication showed falls in total and low density lipoprotein cholesterol ranging from 11·6 to 38·8% and 5·3 to 49'5%, respectively. In view of the condition's association with coronary heart disease and hypercholesterolaemia, it may be worthwhile identifying carriers attending lipid clinics, so that affected siblings can be offered cholesterol-lowering treatment where necessary.
INTRODUCTION
The concentration of plasma cholesterol is mainly regulated by the low density lipoprotein (LDL) receptor pathway in which circulating LDL is taken into the cell by receptor-mediated endocytosis.' Apolipoprotein (a po) B-IOO is the major protein component of LDL, and is the ligand that binds LDL to the LDL receptor.
Familial defective apo B-IOO (FDB), is an autosomal codominant condition associated with increased plasma concentrations of total and LDL cholesterol.v" It is caused by a point mutation, arising from a single base substitution of guanine for adenine at nucleotide 10708 of the apo B-100 gene." This results in the substitution of arginine by glutamine at amino acid 3500 of the apo B-100 protein, resulting in a molecule with reduced binding affinity for the LDL Correspondence: Dr Philip R Wenham. receptor. Consequently LDL particles containing this defective apo B-100 are cleared at a reduced rate resulting in hypercholesterolaemia.P-? Patients with FDB therefore may have clinical features that are similar to those observed in patients with familial hypercholesterolaemia (FH).S-Il
In the present study we have screened 357 hypercholesterolaemic individuals attending lipid clinics in Scotland and Wales for the presence of the FDB mutation. The aim was threefold. First, to ascertain whether the mutation could be detected in a large cohort of hypercholesterolaemic subjects. Second, to identify through family studies and pedigree analysis, the haplotype carrying the mutation. Third, to determine, what proportion of subjects with a clinical and biochemical diagnosis of FH had FDB. In addition, we were also interested in assessing the response of subjects with FDB to treatment with drugs that inhibit cholesterol synthesis and cause an increase in the effective number of functioning LDL receptors.
MATERIALS AND METHODS

Subjects
Blood samples were collected from 357 patients, attending lipid clinics in Scotland (Edinburgh) and Wales (Newport), who were being treated for hypercholesterolaemia. Patients within this group were diagnosed as having FH using the stringent criteria of the Simon Broome Register Group.F These were a total serum cholesterol of > 7·5 mmoljL, a low density lipoprotein cholesterol concentration above 4·9 mmoljL, when available together with the presence of tendon xanthomas either in the patient, first degree relative, or grandparent, uncle or aunt.
Blood samples Blood was collected, whenever possible, after an overnight fast and either anticoagulated with potassium-EDTA (1'2mgjmL) or allowed to clot and the serum separated by centrifugation.
Lipid analyses
Pre-and post-treatment serum cholesterol, triglyceride and high density lipoprotein (HDL) cholesterol (after precipitation of LDL and very low density lipoprotein with phosphotungstic acid and magnesium sulphate) were determined by standard enzymatic techniques. Both centres used identical methods and reagents and all analyses were carried out on Hitachi analysers (Boehringer Mannheim, East Sussex, UK). Exchange of samples showed no significant difference in the lipid levels reported by the two departments. LDL cholesterol was determined using the Friedewald equation." For comparative purposes, the upper limit of the reference range for serum cholesterol and LDL cholesterol was taken to be 6·7 mmoljL and 5'OmmoljL, respectively, for both men and women. 10 DNA analyses DNA was isolated from peripheral whole blood by the method of Miller et al. 14 Apo B-100 genotyping at codon 3500 was performed using the procedure of Motti et al. 15 A negative control (all reagents except DNA) was included in each batch of 20 reactions to exclude contamination. When a sample tested positive for the mutation, the result was confirmed using DNA obtained from a second blood sample. Apo B genotypes were determined at three Ann cu« Biochem 1996: 33 biallelic polymorphic sites flanking codon 3500 of the apo B-100 gene and identified by the restriction endonucleases Xba I (codon 2488),16 Msp I (codon 3611)17 and Eco RI (codon 4154).18 Alleles were identified as positive or negative, depending on whether or not the particular restriction site was present. The haplotype associated with the FDB mutation was determined by segregation analysis of the alleles witin the FDB-affected families. The assumption was made that no recombination event had occurred between the mutation in codon 3500 of the apo B gene and the other polymorphic sites. In the FDB-affected families, haplotypes were constructed at the LDL receptor locus, using four restriction fragment length polymorphisms (RFLPs), identified by the restriction endonucleases Stu I, Ava 11,19 Sma 1 20 and Hinc 11. 21 Cosegregation analysis was performed between individuals with hypercholesterolaemia and the corresponding LDL receptor haplotype.
Statistical analyses
In family studies, differences in total serum cholesterol concentrations between subjects with and without FDB were tested using the Mann-Whitney two sample test. Differences in total and LDL cholesterol concentrations before and after drug therapy were tested by one way analysis of variance. All statistical calculations were carried out using the MINITAB Statistical Package (State College of Pennsylvania). Statistical significance was considered to be at the 0·05 level.
RESULTS
Apo B genotyping at codon 3500
The 357 individuals who were screened for the presence of the FDB mutation had a mean cholesterol of 10·0 mmol(L (SD 1·73, range 7· 1-17'6 mmoljL). Forty-eight individuals were considered to be heterozygous for FH, using the above criteria; one FDB heterozygote was identified from this group. The remaining 309 individuals had Type II hyperlipidaemia of unknown causes, and from these, six FDB heterozygotes were identified (Table I) . The frequency of the FDB mutation was 2·0% (seven of 357) in the combined total populations of both clinics, and 2·1% (one of 48) in the combined subset of patients with a clinical diagnosis of FH. Thirty-four individuals from the families of all seven index cases gave consent to be screened for the FDB mutation and a further II heterozygotes were identified. The clinical and biochemical features of the seven probands and affected and unaffected family members are shown in Table 2 . Pre-treatment serum cholesterol ranged from 5·7-11·2 mmoljL, mean (SD) 8·5 (1'5) mmoljL, in the FDB-carriers and from 3·4-7·8mmoljL, mean 5·7 (1'2)mmoljL, in the unaffected individuals. This difference was highly significant (P<O·OOOOI). Of the II identified heterozygous relatives of the seven index cases, nine had serum cholesterol levels greater than 6'7mmoljL, indicating a penetrance of 82%. One of these (RJ, family W4) was not hypercholesterolaernic when her cholesterol was first measured in August 1993, the result being 5·2 mmoljL, but 13 months later this had risen to 7·OmmoljL.
Five of the seven families had a history of premature coronary heart disease (CHD) and three heterozygous individuals suffered CHD. CP (family WI) had four myocardial infarctions since the age of 55; GP (family W2) underwent coronary artery bypass grafting at the age of 40; and DL (family S3) developed angina at the age of 47. FL (family S2) suffered a cerebrovascular accident at age 48. A further three subjects AE (family SI), AL (family S2) and MnP (family WI) were under treatment for hypertension. One of the 18 heterozygotes had tendon xanthomata, MnP (family WI); three had corneal arcus, AE (family Sl), MT (family WI) and CP (family WI).
Pedigree analysis
Three of the seven families were informative and using linkage analysis, the haplotype carrying the FDB mutation was identified in each family as follows: Xba 1-, Msp 1+, Eco RI -. The remaining four families were uninformative Response of FDB heterozygotes to lipid-lowering medication Eleven FDB heterozygotes were receiving both dietary advice and lipid-lowering medication. Table 3 shows their lipid levels on diet alone and then after at least 3 months medication when lipid levels had stabilized. Total serum cholesterol fell from 9·2 to 7·1 mmoljL, a mean total fall of 2·1 mmoljL (95% CI 1·51, 2·69; P<O·OOI). Serum concentrations of LDL cholesterol fell from 7·2 to 4·9 mmoljL, a mean fall of2'3mmoljL (95% CI 1·37,3·1; P<O·OOI).
DISCUSSION
A total of 357 unrelated individuals from the two lipid clinics were screened for the presence of the FDB mutation. Using the strict criteria of the Simon Broome Register Group, only 48 of the 357 hypercholesterolaemic individuals were classified clinically as having FH; of whom only one FDB heterozygote was found. The estimated prevalence of the FDB mutation is reported to be between one in 500 and one in 1300 3.8 • 22,23 depending on the population studied; this is not dissimilar to the reported prevalence of FH.24 Thus, the number of FDB mutations amongst the individuals diagnosed as having FH is much lower than predicted on the basis of these prevalence figures, if it is assumed that FDB patients always present with the clinical features of FH. In fact, the frequency of the FDB mutation in our FH group (one in 48) is similar to the reported two FDB mutations observed in a population of 101 FH patients in one study-' and six in a population of 173 FH patients in another.! The clinical picture of FH appears to occur in a relatively small but constant proportion of patients who carry the FDB mutation.
The remaining six individuals with the FDB mutation, four of whom had a family history of early onset CHD, were found amongst the 309 hypercholesterolaemic individuals who did not male 73-year-old whose first MI occurred at age satisfy the strict criteria used to define FH. Of 55, and a 47-year-old male. Clearly, whilst only a these six individuals, one male (age 40) had minority of FDB patients may satisfy the clinical premature CHD. In addition, two of the II FDB criteria for the diagnosis of FH, hypercholestercarriers identified also had premature CHD, one olaemicpatients with FDB represent about 2% of the hypercholesterolaernic group in our study and are almost certainly at increased risk of CHO compared to the population as a whole. At present. data is insufficient to know if the CHO risk in the FOB heterozygotes is greater than that predicted on the basis of raised cholesterol alone.
In all of the families we studied. the FOB mutation was present on the haplotype previously identified in all but one of the FOB families in Europe.4.10.25.2b This is consistent with the mutation having been inherited from a common distant ancestor.
All of the FOB heterozygotes responded to treatment for hyperlipidaemia, with mean falls in total and LOL cholesterol of 23 and 30%. respectively. These decreases are greater than those of 12 and 16% described by Corsini et alY and similar to those reported in the three most recent studies. 2K .lO where mean falls in LOL cholesterol of 29%. 27·8% and 32%. respectively were obtained. As this was not a comparative exercise. individuals with other forms of hyperlipidaemia such as FH were not studied. Whilst the number of patients we studied was small and regression to the mean was not taken into account in analysing the results. the marked fall in both total and LOL cholesterol on treatmentt undoubtedly reflects a true response to lipid-lowering medication.
In conclusion. we have shown that the point mutation believed to be the cause of FOB. is present in the Scottish and Welsh populations and appears to have originated in a common ancestor many years ago, Contrary to earlier predictions," individuals heterozygous for the mutation respond very well to treatment with lipid-lowering drugs that act secondarily by increasing the number of functioning LDL receptors. In view of its apparent association with familial premature CHD, screening for FDB should be considered in those individuals and their siblings with a family history of hypercholesterolaemia or atherosclerosis, so that carriers may be identified and offered Iipidlowering medication.
